REVISIONS TO MINIMUM ENROUTE IFR ALTITUDES AND CHANGEOVER POINTS—Continued

[Amendment 387 Effective Date, February 2, 1995]

From	To	MEA
*1600—MOCA		
§ 95.6445 VOR Federal Airway 445 is amended to read in part		
Somto, PA Fix	Yardley, PA Vortac	*2400
*1600—MOCA		

From	To	MEA	MAA
§ 95.7002 Jet Route No. 2 is amended to read in part			
Lake Charles, LA Vortac	Semmes, AL Vortac	18000	45000
§ 95.7031 Jet Route No. 31 is amended by adding			
Leeville, LA Vortac	Harvey, LA Vortac	18000	45000
Harvey, LA Vortac	Meridian, MS Vortac	18000	45000
is amended to delete			
New Orleans, LA Vortac	Meridian, MS Vortac	18000	45000
§ 95.7035 Jet Route No. 35 is amended by adding			
Leville, LA Vortac	McComb, MS Vortac	1800	45000
is amended to delete			
New Orleans, LA Vortac	McComb, MS Vortac	18000	45000
§ 95.7037 Jet Route No. 37 is amended to read in part			
Hobby, TX VOR/DME	Harvey, LA Vortac	18000	45000
Harvey, LA Vortac	Semmes, AL Vortac	18000	45000
§ 95.7058 Jet Route No. 58 is amended to read in part			
Alexandria, LA Vortac	Harvey, LA Vortac	18000	45000
Harvey, LA Vortac	*NEPTA, FL Fix	18000	45000

[FR Doc. 95–1613 Filed 1–20–95; 8:45 am]
BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Trenbolone Acetate and Estradiol

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Roussel-Uclaf. The NADA provides for use of an ear implant containing trenbolone acetate and estradiol for heifers fed in confinement for slaughter for increased rate of weight gain and improved feed efficiency.

EFFECTIVE DATE: January 23, 1995.

FOR FURTHER INFORMATION CONTACT: Jack Caldwell, Center for Veterinary Medicine (HFV–126), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1638.

SUPPLEMENTARY INFORMATION: Roussel-Uclaf, Division Agro-Veterinaire, 163 Avenue Gambetta, 75020, Paris, France, represented in the United States by Hoechst-Roussel Agri-Vet Co., Rt. 202–206, P.O. Box 2500, Somerville, NJ 08876–1258, filed NADA 140–992 which provides for use of an ear implant containing 7 pellets, each pellet containing 20 milligrams (mg) of trenbolone acetate and 2 mg of estradiol. The implant is used in heifers fed in confinement for slaughter for increased rate of weight gain and improved feed efficiency. The NADA is approved as of December 13, 1994, and the regulations are amended in 21 CFR 522.2477 to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for a 3-year period of marketing exclusivity beginning on December 13, 1994, because new clinical or field investigations (other than bioequivalence or residue studies), or human food safety studies (other than bioequivalence or residue studies) essential to the approval were

conducted or sponsored by the applicant.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

2. Section 522.2477 is revised to read as follows:

§ 522.2477 Trenbolone acetate and estradiol.

(a) *Sponsor.* See No. 012579 in § 510.600(c) of this chapter.

(b) *Related tolerances.* See §§ 556.240 and 556.739 of this chapter.

(c) *Conditions of use*—(1) *Feedlot steers*—(i) *Amount.* 120 milligrams of trenbolone acetate and 24 milligrams of estradiol (6 pellets, each pellet containing 20 milligrams of trenbolone acetate and 4 milligrams of estradiol) per animal.

(ii) *Indications for use.* For increased rate of weight gain and improved feed efficiency in feedlot steers.

(iii) *Limitations.* Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.

(2) *Heifers*—(i) *Amount.* 140 milligrams of trenbolone acetate and 14 milligrams of estradiol (7 pellets, each pellet containing 20 milligrams of trenbolone acetate and 2 milligrams of estradiol) per animal.

(ii) *Indications for use.* For increased rate of weight gain and improved feed efficiency in heifers fed in confinement for slaughter.

(iii) *Limitations.* Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.

Dated: January 13, 1995.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 95–1654 Filed 1–20–95; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF THE TREASURY

Fiscal Service

31 CFR Parts 306 and 357

General Regulations Governing U.S. Securities and Regulations Governing Book-Entry Treasury Bonds, Notes and Bills

AGENCY: Bureau of the Public Debt, Fiscal Service, Treasury.

ACTION: Final rule.

SUMMARY: This final rule amends the general regulations governing United States securities and the regulations governing book-entry Treasury securities to implement a provision of the Treasury, Postal Service and General Government Appropriations Act of 1995. The legislation authorizes the Treasury to collect a fee for each definitive Treasury security issued to customers, and to collect an annual fee for each TREASURY DIRECT securities account that exceeds a stipulated amount.

EFFECTIVE DATE: January 23, 1995.

FOR FURTHER INFORMATION CONTACT: Maureen Parker, Director, Division of Securities Systems, Bureau of the Public Debt, (304) 480–7761; Susan Klimas, Attorney-Adviser, Office of the Chief Counsel, Bureau of the Public Debt, (304) 480–5192.

SUPPLEMENTARY INFORMATION: The Treasury, Postal Service and General Government Appropriations Act of 1995 (Pub. L. 103–329), authorizes the Secretary to collect a fee of not less than $46 for each definitive security issued to customers. The general regulations governing United States securities are contained in 31 CFR Part 306. A definitive security is a Treasury bond, note, certificate of indebtedness, or bill issued in engraved or printed form. Although securities in definitive form are no longer available on original issue, certain older issues of Treasury securities, by the terms of their issue, are still available in definitive form. The fees are to be imposed on each definitive security issued or reissued upon the request of a customer, to enable the Department to recoup the costs connected with such issuance. The fees must be paid in full when the transaction is requested. The Department intends to begin the collection of these fees on January 30, 1995.

Therefore, Part 306 is amended by adding a new Section 306.24, to provide that a fee will be charged for each definitive security issued as a result of a transfer, reissue, exchange or withdrawal from book-entry form, or the granting of relief on account of loss or theft, in accordance with a fee schedule. The fee schedule applicable appears separately as a notice in this issue of the **Federal Register**. Future fee schedule changes, if any, will be announced through a notice published in the **Federal Register**.

The Treasury, Postal Service and General Government Appropriations Act of 1995 (Pub. L. 103–329) also authorizes the Secretary to collect an annual fee of not less than $25.00 for each Treasury Direct Investor Account in the Treasury Direct book-entry securities system which exceeds $100,000 (par value). The regulations governing such securities are contained in 31 CFR Part 357. The category of accounts covered by the legislation is referred to in Part 357 as a ''Securities account'', and defined in Section 357.20. Fees will be charged to reduce the cost of maintaining large Treasury Direct Investor Accounts. A bill will be mailed to the investor for each account subject to the charge. The Department intends to begin the collection of these fees for accounts in the applicable amount as of May 19, 1995.

Accordingly, Part 357 is amended to add new paragraph (f) to Section 357.20. Paragraph (f) provides that accounts above a stipulated par amount will be charged a fee. The accounts to which the fee will apply, and the amount of such fee, are published separately as a notice in this issue of the **Federal Register**.

Procedural Requirements

It has been determined that this final rule does not meet the criteria for a ''significant regulatory action,'' as defined in Executive Order 12866. Therefore, the regulatory review procedures contained therein do not apply.

This final rule relates to matters of public contract and procedures for U.S. securities, as well as the borrowing power and fiscal authority of the United States. Accordingly, pursuant to 5 U.S.C 553(a)(2), the notice, public comment and delayed effective date provisions of the Administrative Procedure Act do not apply. As no notice of proposed rulemaking is required, the provisions of the Regulatory Flexibility Act (5 U.S.C. 601, *et seq.*) do not apply.